Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man

Janet Dickerson, D. Perrier, Michael Mayersohn, R. Bressler

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Dose tolerance and pharmacokinetic studies of pseudoephedrine sustained action capsules were performed in thirty-three adult male subjects who received either 120 mg or 150 mg capsules every twelve hours for seven consecutive days in a double-blind parallel design study. Although only one subject in the 150 mg group was discontinued prematurely from this study, a large number of side effects typical of CNS stimulation were seen. A placebo effect might account for a portion of these complaints, however symtoms evaluated as being due to drug were significantly more severe and persistent in the 150 mg group. Pulse rates showed a persistent and significant increase while systolic and diastolic blood pressure fell from the baseline values in both groups. A pharmacokinetic analysis of the pseudoephedrine plasma concentration-time data provided estimates of half-life and the volume of distribution/availability ratio. The values obtained were in good agreement with values reported by others. Half-life was not influenced by urine pH probably as a result of the narrow range of urine pHs observed in the subjects. Calculations of relative bioavailability suggest that the 120 mg capsule formulation has a 30% greater bioavailability compared to the 150 mg capsule.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume14
Issue number4
DOIs
StatePublished - Jul 1978

Fingerprint

Pseudoephedrine
Capsules
Pharmacokinetics
Biological Availability
Half-Life
Urine
Blood Pressure
Placebo Effect
Heart Rate
Pharmaceutical Preparations

Keywords

  • bioavailability
  • multiple oral dosing
  • Pseudoephedrine
  • side effects

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man. / Dickerson, Janet; Perrier, D.; Mayersohn, Michael; Bressler, R.

In: European Journal of Clinical Pharmacology, Vol. 14, No. 4, 07.1978, p. 253-259.

Research output: Contribution to journalArticle

@article{4427dc2a276c4226a5bf7f82f280152c,
title = "Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man",
abstract = "Dose tolerance and pharmacokinetic studies of pseudoephedrine sustained action capsules were performed in thirty-three adult male subjects who received either 120 mg or 150 mg capsules every twelve hours for seven consecutive days in a double-blind parallel design study. Although only one subject in the 150 mg group was discontinued prematurely from this study, a large number of side effects typical of CNS stimulation were seen. A placebo effect might account for a portion of these complaints, however symtoms evaluated as being due to drug were significantly more severe and persistent in the 150 mg group. Pulse rates showed a persistent and significant increase while systolic and diastolic blood pressure fell from the baseline values in both groups. A pharmacokinetic analysis of the pseudoephedrine plasma concentration-time data provided estimates of half-life and the volume of distribution/availability ratio. The values obtained were in good agreement with values reported by others. Half-life was not influenced by urine pH probably as a result of the narrow range of urine pHs observed in the subjects. Calculations of relative bioavailability suggest that the 120 mg capsule formulation has a 30{\%} greater bioavailability compared to the 150 mg capsule.",
keywords = "bioavailability, multiple oral dosing, Pseudoephedrine, side effects",
author = "Janet Dickerson and D. Perrier and Michael Mayersohn and R. Bressler",
year = "1978",
month = "7",
doi = "10.1007/BF00560458",
language = "English (US)",
volume = "14",
pages = "253--259",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man

AU - Dickerson, Janet

AU - Perrier, D.

AU - Mayersohn, Michael

AU - Bressler, R.

PY - 1978/7

Y1 - 1978/7

N2 - Dose tolerance and pharmacokinetic studies of pseudoephedrine sustained action capsules were performed in thirty-three adult male subjects who received either 120 mg or 150 mg capsules every twelve hours for seven consecutive days in a double-blind parallel design study. Although only one subject in the 150 mg group was discontinued prematurely from this study, a large number of side effects typical of CNS stimulation were seen. A placebo effect might account for a portion of these complaints, however symtoms evaluated as being due to drug were significantly more severe and persistent in the 150 mg group. Pulse rates showed a persistent and significant increase while systolic and diastolic blood pressure fell from the baseline values in both groups. A pharmacokinetic analysis of the pseudoephedrine plasma concentration-time data provided estimates of half-life and the volume of distribution/availability ratio. The values obtained were in good agreement with values reported by others. Half-life was not influenced by urine pH probably as a result of the narrow range of urine pHs observed in the subjects. Calculations of relative bioavailability suggest that the 120 mg capsule formulation has a 30% greater bioavailability compared to the 150 mg capsule.

AB - Dose tolerance and pharmacokinetic studies of pseudoephedrine sustained action capsules were performed in thirty-three adult male subjects who received either 120 mg or 150 mg capsules every twelve hours for seven consecutive days in a double-blind parallel design study. Although only one subject in the 150 mg group was discontinued prematurely from this study, a large number of side effects typical of CNS stimulation were seen. A placebo effect might account for a portion of these complaints, however symtoms evaluated as being due to drug were significantly more severe and persistent in the 150 mg group. Pulse rates showed a persistent and significant increase while systolic and diastolic blood pressure fell from the baseline values in both groups. A pharmacokinetic analysis of the pseudoephedrine plasma concentration-time data provided estimates of half-life and the volume of distribution/availability ratio. The values obtained were in good agreement with values reported by others. Half-life was not influenced by urine pH probably as a result of the narrow range of urine pHs observed in the subjects. Calculations of relative bioavailability suggest that the 120 mg capsule formulation has a 30% greater bioavailability compared to the 150 mg capsule.

KW - bioavailability

KW - multiple oral dosing

KW - Pseudoephedrine

KW - side effects

UR - http://www.scopus.com/inward/record.url?scp=0018241207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018241207&partnerID=8YFLogxK

U2 - 10.1007/BF00560458

DO - 10.1007/BF00560458

M3 - Article

VL - 14

SP - 253

EP - 259

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 4

ER -